CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Businesses  /  Novel Biologics

NOVEL BIOLOGICS

Enabling cutting edge therapies

Biocon’s path-breaking work in novel biologics and novel targets in large molecules has seen significant results in diabetes, oncology and immunology. The novel biologics portfolio includes both, in-house as well as partnered and in-licensed products.

null

Bicara Therapeutics, a wholly owned subsidiary of Biocon based in Boston, U.S., is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara enables access to the thriving innovation ecosystem in the U.S. which accelerates our development of cutting-edge therapies for cancer. Synergies between the scientific teams in Boston and Bengaluru will pioneer rapid and cost-effective breakthrough innovation.

global innovations

In-house research capabilities

Access to novel IP, therapeutic modalities, in-vivo and in-vitro models

Toxicology studies

Early regulatory filings

Academic collaborations

novel assets

Monoclonal antibodies against novel targets like CD6, against established targets like CD20 and EGFR

Bispecific fusion antibodies that explore the role of checkpoint inhibitors

Insulin Tregopil, our orally delivered insulin analog, that is making clinical progress

Novels Biologics

BUSINESS INTENT

create market leadership in innovation e.g. Insulin Tregopil, Itolizumab

PIPELINE

oral insulin, mAbs against targets like CD6, CD20 & EGFR; bi-specific fusion mAbs

POTENTIAL

to change the treatment paradigm in diabetes, inflammation and auto-immunology

null

Biocon & Novels

We are the pioneers in developing, manufacturing and launching BIOMAb-EGFR®, India’s first indigenously produced novel monoclonal antibody for the treatment of head and neck cancer; and ALZUMAb™, the world’s first novel anti-CD6 monoclonal antibody in India, for psoriasis.

More >> 

null

Novels In Pipeline

Our novel biologics under clinical development focus on treatments in diabetes, autoimmune/ inflammation and oncology. These represent a combination of early and advanced stage assets.

More >>

FINANCIAL CALENDAR
KEY THERAPEUTIC AREAS
OUR KEY PRIORITIES
BOARD OF DIRECTORS
PRESS RELEASES
Share